Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | compounds already reach it: afimetoran, motolimod, resiquimod +4 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 1,734 | 0.76 |
| pathways Reactome | 3 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 9446
Sealed predictions
- TLR8 in dopamine neurons, braak+0.44 (p 0.232) → -0.13 (p 0.732)receipt 9454
Swarm cases
receipt 9454: TLR8 in dopamine neurons, braak
- power
- full sample +0.25 (p 0.319, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.31 (p 0.204, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.30 (p 0.221, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.35, sign flips 0; without severely affected donors +0.25 (p 0.319, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TLR8 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts